Famitinib

Famitinib
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 5-[2-(Diethylamino)ethyl]-2-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-3-methyl-6,7-dihydro-1H-pyrrolo[3,2-c]pyridin-4-one;
CAS Number	1044040-56-3;
PubChem CID	16662431;
IUPHAR/BPS	7886;
DrugBank	DB11741;
ChemSpider	17595500;
UNII	768FW21J3L;
ChEMBL	ChEMBL1278146;
CompTox Dashboard (EPA)	DTXSID301358976 ;
Chemical and physical data
Formula	C23H27FN4O2
Molar mass	410.493 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(CC)CCN1CCC2=C(C1=O)C(=C(N2)/C=C\3/C4=C(C=CC(=C4)F)NC3=O)C;
	InChI InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-; Key:GKEYKDOLBLYGRB-LGMDPLHJSA-N;

Famitinib is a tyrosine kinase receptor inhibitor developed by Jiangsu Hengrui for a variety of cancers. In China, in May 2025 famitinib was conditionally approved for use in combination with camrelizumab for the treatment of recurrent or metastatic cervical cancer in patients who have failed prior platinum-based chemotherapy and have not received prior bevacizumab.